A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.

To provide a phosphatidylcholine transdermal absorption preparation containing phosphatidylcholine in an adhesive layer. A phosphatidylcholine transdermal absorption preparation has a configuration in which an adhesive layer formed on at least one side of a support contains phosphatidylcholine, an adhesive component, and a lipophilic component, and thus the preparation becomes a patch-type transdermal absorption preparation which acts as a fat-decreasing agent which contains phosphatidylcholine and can exert an effect that local obesity such as subcutaneous fat is dissolved and fat is decreased by transdermal absorption of phosphatidylcholine as the preparation is pasted to the skin of a human body since phosphatidylcholine can be stably present in the adhesive layer and has an advantage due to the patch dosage form that the preparation can be fixed to the affected area and is more favorably handled as compared to liquid preparations and the like.

An object of the present invention is to provide a patch preparation having an excellent skin permeability of medicament using an acid additional salt of basic medicament. Provided is a patch preparation comprising a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a basic medicament, a fatty acid-based ionic liquid, and potassium salts and/or potassium ions. Said potassium salts and/or potassium ions are generated as a result of reaction of an acid addition salt of the basic medicament with a compound capable of generating potassium ion in the adhesive layer.

The present invention provides the following compounds having anti-viral activity. ##STR00001##
A.sup.1 is CR.sup.1AR.sup.1B, S or O;
A.sup.2 is CR.sup.2AR.sup.2B, S or O;
A.sup.3 is CR.sup.3AR.sup.3B, S or O;
A.sup.4 is CR.sup.4AR.sup.4B, S or O;
the number of hetero atoms among atoms constituting the ring which consists of A.sup.1, A.sup.2, A.sup.3, A.sup.4, nitrogen atom adjacent to A.sup.1 and carbon atom adjacent to A.sup.1, is 1 or 2;
R.sup.1A and R.sup.1B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.2A and R.sup.2B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.3A and R.sup.3B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.4A and R.sup.4B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.3A and R.sup.3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle;
X is CH.sub.2, S or O;
R.sup.1 is each independently halogen, hydroxy, or the like;
m is any integer of 0 to 2; and
n is any integer of 1 to 2.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren (diclofenac) ointment; therefore the proposed formula has promising clinical application.

Compositions and methods for the treatment and/or prevention and/or control of indications such as pain management, cancer, seizure disorders, and Parkinson's Disease using continuous drug delivery.

The invention provides methods for directing a localized biological response of a mammalian body to an implant disposed within the body. In one embodiment, a delivery system is positioned outside the body and adjacent to the implant within the body. The delivery system comprises a first tissue response modifier effective for directing a localized biological response of the body to the implant. The tissue response modifier is nonsurgically delivered from the delivery system into the body in a quantity effective to direct the localized biological response of the body to the implant. The invention also provides an implant system for long-term use comprising an implant and nonsurgical means for delivering a tissue response modifier through the epidermis of the body, the tissue response modifier effective for directing a localized biological response of the body to the implant.

Dosing regimens for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval are disclosed.

Dosing regimens for transdermal delivery of hormones comprising a variable treatment cycle and a fixed rest interval are disclosed.

A medicated patch applicator includes a portable handle having a centrally registered longitudinal axis, a flexible frame pivotally connected to the handle and selectively articulated relative thereto, and an implement adjustably coupled to a distal end of the handle and disposed at a proximal end of the frame. Such an implement is located adjacent to a juncture of the frame and the handle such that the implement linearly protrudes outwardly from the handle along the centrally registered longitudinal axis. Advantageously, the implement is capable of removing an existing back liner of an existing medicated patch during an application process of the existing medicated patch.